Dr. Jianjun Zou, General Manager and CEO of Junshi Biosciences, said: “Based on the ‘Ten Perfections’, Toripalimab continues to make breakthroughs and has been officially approved for its 11th indication, which makes us very excited! As the country with the heaviest burden of liver cancer in the world, liver cancer patients in China have long faced the dilemma of limited treatment options. Junshi Biosciences has long focused on the clinical needs in the field of liver cancer treatment worldwide, and has arranged clinical studies using multi-combination strategies for different disease course populations, aiming to provide liver cancer patients with more accurate and richer treatment options. We will continue to be committed to drug innovation in this field and inject more powerful ‘Chinese wisdom’ into the fight against liver cancer.”